Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service lumbar fusion cases in Utah: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (237 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 32 | 1,336 | 41% |
| 2020 | 27 | 1,243 | 44% |
| 2021 | 29 | 1,139 | 48% |
| 2022 | 32 | 1,260 | 51% |
| 2023 | 27 | 1,164 | 54% |
| 2024 | 27 | 1,172 | 57% |
| 2025 from claims | – | 1,152 1,055–1,223 | 59% |
| 2026 forecast | – | 1,155 1,017–1,328 | 60% |
| 2027 forecast | – | 1,159 992–1,375 | 61% |
| 2028 forecast | – | 1,163 971–1,416 | 62% |
| 2029 forecast | – | 1,166 953–1,453 | 62% |
| 2030 forecast | – | 1,168 936–1,487 | 63% |
Posterolateral, interbody, and anterior lumbar fusion with instrumentation. Professional codes (what the surgeon bills): CPT 22612, 22630, 22633, 22558; the hospital bills MS-DRG 453, 454, 455, 459, 460, 402, 426, 427, 428, 447, 448, 450, 451, 523, 524, 525.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 64% of the cases CMS names in Utah; 16 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 82% inpatient hospital, 17% hospital outpatient, 1% surgery center.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 199 | 8,729−0.8%/yr | −0.8%/yr | 2.5 | 2% | 9,000 in 2030+0.5%/yr |
| Arizona | 68 | 2,850+1.4%/yr | +1.4%/yr | 3.7 | 2% | 3,430 in 2030+3.1%/yr |
| Colorado | 67 | 2,338−3.7%/yr | −3.7%/yr | 4.6 | 1% | 2,610 in 2030+1.8%/yr |
| Washington | 49 | 1,976−4.2%/yr | −4.2%/yr | 2.5 | 1% | 1,960 in 2030−0.1%/yr |
| Oregon | 23 | 1,034−3.1%/yr | −3.1%/yr | 2.4 | 2% | 960 in 2030−1.2%/yr |
| Nevada | 24 | 954−1.4%/yr | −1.4%/yr | 3.2 | 2% | 760 in 2030−3.7%/yr |
| Idaho | 21 | 880+2.8%/yr | +2.8%/yr | 4.2 | 2% | 1,310 in 2030+6.8%/yr |
| Montana | 16 | 502−0.8%/yr | −0.8%/yr | 2.6 | 0% | 540 in 2030+1.1%/yr |
| New Mexico | 8 | 289+0.6%/yr | +0.6%/yr | 1.2 | 0% | 180 in 2030−7.3%/yr |
| Alaska | 7 | 253+6.1%/yr | +6.1%/yr | 2.1 | 0% | 390 in 2030+7.5%/yr |
| Wyoming | 6 | 249−4.7%/yr | −4.7%/yr | 2.3 | 8% | 280 in 2030+1.8%/yr |
| Hawaii | 4 | 120−4.1%/yr | −4.1%/yr | 0.9 | 36% | 140 in 2030+3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 31 | 1,147−5.6%/yr | −5.6%/yr | 5.11.6× | 16% | 1,350 in 2030+2.8%/yr |
| Kyphoplasty & vertebroplasty | 8 | 523−1.8%/yr | −1.8%/yr | 2.32.7× | 89% | 630 in 2030+3.1%/yr |
| Cervical fusion & disc arthroplasty | 9 | 445−2.8%/yr | −2.8%/yr | 2.01.6× | 17% | 570 in 2030+4.3%/yr |
Lumbar fusion in every state, and its device makers · Every procedure market in Utah · Every state · Compare with California
Globus Medical leads with 22% of company spending on these surgeons in 2025, +10 pts on 2024.
In 2025, 16 companies reported engagement with Utah’s surgeons worth $250K in consulting, speaking, meals and travel tied to these products, about $9,255 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 87 clearances and approvals in the category, 12 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.